Cialis: first PDE5 inhibitor licensed for benign prostatic hyperplasia

Tadalafil (Cialis) has been approved for the treatment of benign prostatic hyperplasia (BPH).

Tadalafil (Cialis) provides a new treatment option for the management of benign prostatic hyperplasia | SCIENCE PHOTO LIBRARY
Tadalafil (Cialis) provides a new treatment option for the management of benign prostatic hyperplasia | SCIENCE PHOTO LIBRARY

The phosphodiesterase 5 inhibitor is thought to relieve BPH symptoms by relaxing smooth muscle and increasing blood flow to the bladder, prostate and urethra.

Efficacious from as early as week one

The efficacy and safety of tadalafil in BPH was displayed in four 12-week clinical studies that enrolled over 1,500 men. In each study, treatment with tadalafil 5mg daily improved total International Prostate Symptom score by around two points more than placebo, with improvements being observed as early as week one.

Suitable for BPH with erectile dysfunction

Cialis can be used in patients with BPH who require treatment for erectile dysfunction (ED) as the 5mg once-daily dose is licensed for both indications, provided the patient requires frequent use in ED (at least twice weekly).

View Cialis drug record
 
Further information: Lilly Eli & Co Ltd

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Male clinician in white coat showing female patient how to use IQoro device.

Training device for reflux and dysphagia available on NHS

A neuromuscular training device for patients with reflux-based...

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...